id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-331831-gw42e6ce	Moore, Luke S P	Near-patient SARS-CoV-2 molecular platforms: new-old tools for new-old problems	2020-10-08		.txt	text/plain	1101	53	48	In their prospective, interventional, non-randomised, controlled trial published in The Lancet Respiratory Medicine, Nathan Brendish and colleagues 1 move COVID-19 diagnostics forward, both by expanding the repertoire of in-situ evaluated molecular platforms, and also methodologically, with a diagnostic controlled trial using clinical impact as a primary outcome measure, analogous to their previous work on other respiratory viruses. 1 Nevertheless, this level of accuracy is attractive in the context of the recently published (yet perhaps already outdated) Cochrane review 3 of early-tomarket, rapid, point-of-care molecular tests for SARS-CoV-2, which looked at 13 evaluations of four platforms, finding a mean sensitivity of 95·2% (86·7-98·3) with a specificity of 98·9% (97·3-99·5). Brendish and colleagues also showed that the fast turnaround time of the QIAstat-Dx Respiratory SARS-CoV-2 Panel decreased the time taken for patients to be placed in an appropriate care area, and led to fewer bed moves and faster time to enrolment into other COVID-19 clinical trials-all significant advantages. Clinical impact of molecular point-ofcare testing for suspected COVID-19 in hospital (COV-19POC): a prospective, interventional, non-randomised, controlled study	./cache/cord-331831-gw42e6ce.txt	./txt/cord-331831-gw42e6ce.txt